NCT03361748 · OUTCOME

Overall Response Rate

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: 95% Confidence Interval
Time frame: From first dose to 24 Months

What was measured

Number of participants who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an independent response committee (IRC).

Analysis population: All Treated Participants

Groups in this outcome

BB2121

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
BB2121	137

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
BB2121	74.5	Not reported	67.1	81.8	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
67.1
upper Limit
81.8
value
74.5

denoms

counts
group Id
OG000
value
137
units
Participants

description

Number of participants who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an independent response committee (IRC).

dispersion Type

95% Confidence Interval

groups

description
BB2121
id
OG000
title
BB2121

param Type

NUMBER

population Description

All Treated Participants

reporting Status

POSTED

time Frame

From first dose to 24 Months

title

Overall Response Rate

type

PRIMARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice